CytoMed Therapeutics Limited (GDTC) Key Metrics
GDTC key metrics, 2019–2025
Fiscal year ended December 31, 2025 · Singapore dollarsGDTC returns How much profit the business earns on the capital it uses.
GDTC financial health Debt, liquidity and how easily interest is covered.
GDTC efficiency & capital use Working capital cycle and where the cash goes.
GDTC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GDTC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GDTC key metrics in Singapore dollars
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Returns & profitability | |||||||
| Return on equity (ROE) | −50.5% | −24.9% | −69.9% | −191.7% | −134.9% | −161.0% | −44.4% |
| Return on invested capital (ROIC) | −76.1% | −69.0% | −42.0% | −54.9% | −31.2% | −44.8% | −23.9% |
| Return on assets (ROA) | −43.4% | −22.4% | −46.9% | −53.8% | −41.8% | −57.4% | −29.2% |
| Return on tangible assets | −49.8% | −25.2% | −33.4% | −58.4% | −34.2% | −51.4% | −29.5% |
| Free cash flow margin | — | — | −707.0% | −514.5% | — | — | — |
| Financial health | |||||||
| Total debt | S$482,562 | S$463,147 | S$449,247 | S$4.2M | S$3.3M | S$3.0M | S$674,609 |
| Cash & short-term investments | S$2.1M | S$5.0M | S$9.0M | S$1.6M | S$2.5M | S$930,810 | S$459,222 |
| Net debt | −S$1.6M | −S$4.5M | −S$8.6M | S$2.7M | S$732,405 | S$2.1M | S$215,387 |
| Debt / equity | 0.07 | 0.05 | 0.04 | 7.19 | 1.26 | 6.26 | 0.35 |
| Debt / assets | 0.06 | 0.05 | 0.04 | 0.81 | 0.54 | 0.78 | 0.23 |
| Current ratio | 5.17 | 9.89 | 14.08 | 0.60 | 1.12 | 0.54 | 1.46 |
| Quick ratio | 3.66 | 8.51 | 13.14 | 0.46 | 0.97 | 0.45 | 1.33 |
| Interest coverage | -219.7 | -154.1 | -31.3 | -18.7 | -9.8 | -12.6 | — |
| Working capital | S$3.0M | S$5.4M | S$9.4M | −S$1.7M | S$346,065 | −S$1.3M | S$172,366 |
| Invested capital | S$4.9M | S$4.5M | S$2.7M | S$3.2M | S$3.3M | S$2.5M | S$2.2M |
| Tangible asset value | S$6.7M | S$8.9M | S$11.3M | S$570,132 | S$2.6M | S$431,484 | S$1.9M |
| Net current asset value | S$2.5M | S$5.0M | S$9.0M | −S$2.2M | −S$209,668 | −S$1.9M | −S$458,647 |
| Capital allocation | |||||||
| Dividends paid | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 | — |
| Capex / revenue | 220.3% | 2,014.2% | 11.5% | 130.2% | 693.4% | 546.0% | — |
| Capex / depreciation | 1.75 | 4.17 | 0.15 | 1.21 | 1.77 | 0.84 | 6.61 |
| Stock-based compensation / revenue | 217.5% | 0.0% | 0.0% | — | — | — | — |
| R&D / revenue | 683.6% | 2,747.5% | 313.1% | 416.3% | 1,295.1% | 2,310.7% | — |
| SG&A / revenue | 577.3% | 1,821.1% | 96.3% | 163.2% | 696.1% | 344.7% | — |
| Efficiency | |||||||
| Days sales outstanding | 70.1 | 586.9 | 92.9 | 34.8 | 530.7 | 932.6 | — |
| Days of inventory on hand | 288.5 | 16,194.1 | 61,522.4 | 1,692.8 | 35,111.4 | 11,402.3 | — |
| Days payables outstanding | 24.7 | 674.8 | 1,923.6 | 102.2 | 3,404.6 | 1,238.9 | — |
| Cash conversion cycle (days) | 333.9 | 16,106.2 | 59,691.7 | 1,625.5 | 32,237.5 | 11,096.0 | — |
| Receivables turnover | 5.21 | 0.62 | 3.93 | 10.48 | 0.69 | 0.39 | 0.00 |
| Payables turnover | 14.76 | 0.54 | 0.19 | 3.57 | 0.11 | 0.29 | — |
| Inventory turnover | 1.27 | 0.02 | 0.01 | 0.22 | 0.01 | 0.03 | — |
| Asset turnover | 0.04 | 0.01 | 0.06 | 0.06 | 0.02 | 0.01 | 0.00 |
| Average receivables | S$61,318 | S$111,762 | S$129,642 | S$34,879 | S$122,396 | S$114,786 | S$1 |
| Average payables | S$81,682 | S$31,654 | S$19,690 | S$30,526 | S$32,656 | S$15,705 | S$12,454 |
| Average inventory | S$953,071 | S$759,613 | S$629,720 | S$505,722 | S$336,780 | S$144,544 | S$48,116 |
| Intangibles / total assets | 1.6% | 0.9% | 0.1% | 0.4% | 0.5% | 1.2% | 1.2% |
Computed from GDTC's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Singapore dollars; data from EODHD. Averages use the opening and closing balance of each year.
GDTC valuation and financial ratios
CytoMed Therapeutics earned a return on equity of −50.5% and a return on invested capital of −76.1% in fiscal 2025. It ended the year with S$0.5 million of debt and S$2.1 million in cash and short-term investments, a net cash position of S$1.6 million.
See the GDTC income statement, the GDTC chart for price history, or the GDTC stock overview for the latest quote and news.
GDTC key metrics FAQ
What is CytoMed Therapeutics's return on equity?
CytoMed Therapeutics's return on equity (ROE) was −50.5% in fiscal 2025: net income of -S$3.9 million on average shareholders' equity of S$7.8 million.
What is CytoMed Therapeutics's ROIC?
CytoMed Therapeutics's return on invested capital was −76.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does CytoMed Therapeutics have?
CytoMed Therapeutics had total debt of S$0.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.07 and more cash than debt.
Does CytoMed Therapeutics pay a dividend?
CytoMed Therapeutics did not pay a dividend in fiscal 2025.
What is CytoMed Therapeutics's current ratio?
CytoMed Therapeutics's current ratio was 5.17 at the end of fiscal 2025: current assets were 5.17 times current liabilities.